What Clarix Flo Is
Clarix Flo is described as a sterile, particulate human amniotic membrane and umbilical cord tissue product that is aseptically processed from donated placental tissue and does not contain living cells. It is therefore not a live stem cell injection. Instead, it is a tissue-based allograft designed to deliver matrix support and biologic signals from placental tissue, which places it within the broader regenerative medicine field often discussed alongside stem-cell-related biology.
How Clarix Flo May Work
Placental tissues have attracted medical interest because they may provide growth factors, extracellular matrix proteins, and anti-inflammatory signals that help support tissue repair. Reviews of placental-derived biomaterials report that these tissues can provide an extracellular matrix scaffold, facilitate cell migration, and exert anti-inflammatory effects. In orthopedic language, that means Clarix Flo may help improve the local environment around an irritated joint or soft tissue, and it may help reduce some of the enzymes and inflammatory signals that contribute to cartilage breakdown over time.
May It Involve Stem-Cell-Related Biology?
Many patients ask whether Clarix Flo is a stem cell treatment. The clearest answer is that Clarix Flo itself does not contain living cells, so it should not be described as a live stem cell injection. At the same time, placental and umbilical tissues are part of the same regenerative medicine landscape that includes stem-cell-related biology, because these tissues have been studied for their bioactive matrix, growth factors, and signaling properties.
Why Patients Are Interested
Clarix Flo is appealing because it offers a practical office-based biologic treatment without requiring a blood draw or bone marrow aspiration. The product is prepared as an injectable particulate suspension, so the procedure is simpler than many autologous orthobiologic treatments. Patients who want a treatment that feels more restorative than purely suppressive often find this especially attractive, particularly when they are looking for a next step after exercise, therapy, medications, or standard injections have not delivered enough improvement.
What the Evidence Suggests
The clinical evidence is still early, but published results are encouraging. Studies report that intra-articular injection of amniotic membrane and umbilical cord particulate may relieve pain and improve physical function in patients with symptomatic knee osteoarthritis, including moderate to severe disease. Preclinical work has also shown attenuation of cartilage degradation in an osteoarthritis model, which supports the idea that these tissues may do more than provide temporary symptom masking alone.
What Treatment Is Like
Clarix Flo is typically given as an office-based injection. Because it is an off-the-shelf placental tissue product, there is no separate tissue harvest from your body. That makes the process relatively straightforward and may make it easier for some patients to pursue a regenerative treatment while keeping downtime and procedural complexity lower than with marrow-based procedures.
Recovery and Expectations
Like most orthobiologic treatments, Clarix Flo is best viewed as a therapy that may work gradually rather than instantly. The goal is to improve the biologic environment of the treated area over time, support function, and reduce pain as tissue signaling settles into a healthier pattern. Patients usually do best when the injection is combined with a broader plan that still addresses strength, movement quality, load management, and the mechanical reasons the tissue became irritated in the first place.
FDA and Florida Information
Clarix Flo is processed by BioTissue in FDA-registered facilities that must comply with current good tissue practice (cGTP) standards, which means every step from donor screening through final preparation meets strict federal quality and safety requirements. While the FDA has not approved Clarix Flo specifically for orthopedic joint indications, off-label use of properly processed human tissue allografts is a well-established and accepted practice across many areas of medicine. Florida has created a clear regulatory framework that specifically allows physicians to offer advanced biologic therapies for orthopedic, wound-care, and pain-management purposes, with informed consent and patient protections in place, making it one of the more progressive states for patients seeking regenerative treatment options.
Bottom Line
Clarix Flo is best understood as a placental tissue allograft that may provide extracellular matrix support, growth factors, and regenerative signaling in a painful joint or soft tissue. It is not a live stem cell injection, but it belongs to the same broader regenerative medicine category that patients often explore when they want to avoid surgery and stay active. Early clinical studies in knee osteoarthritis and supportive preclinical data make it a promising option, especially for patients seeking a positive nonsurgical strategy that may help reduce pain, improve function, and possibly slow some of the inflammatory and cartilage-degrading processes that drive ongoing symptoms.
Sources
- BioTissue. Clarix Flo Product Insert.
- Castellanos R, et al. Injectable Amniotic Membrane/Umbilical Cord Particulate for Knee Osteoarthritis.
- Mead OG, et al. Intra-Articular Injection of Amniotic Membrane and Umbilical Cord Particulate in Moderate to Severe Knee Osteoarthritis. 2020.
- Raines AL, et al. Efficacy of Particulate Amniotic Membrane and Umbilical Cord in an Osteoarthritis Model. 2016.
- Protzman NM, et al. Placental-Derived Biomaterials and Their Application to Musculoskeletal Tissue Repair. Bioengineering. 2023.
- U.S. Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies.
- Florida Statutes, Section 458.3245, Stem cell therapy.
- Filardo G, Mandelbaum BR, Muschler GF, Rodeo SA, Nakamura N, eds. Orthobiologics: Injectable Therapies for the Musculoskeletal System. Springer; 2022.